Risk-taking and Dealmaking with Global MedTech Leader, Kevin Lobo

Published: July 13, 2022, 8:01 a.m.

Take risks, keep learning, and stay calm. It\u2019s how our guest, Stryker Chair and CEO Kevin Lobo, became arguably one of the most successful CEOs ever. We\u2019ll talk with the Indian-born, Canadian-raised, internationally acclaimed businessperson about how he became known as the \u201cGodfather of MedTech\u201d and as an acquisitions deal maker. We\u2019ll hear how Kevin\u2019s high threshold for risk helped Stryker drastically outpace the competition and how he built his Board\u2019s trust to make more than 55 acquisitions. Kevin also shares his insights on timely topics leaders in all industries are talking about: technology, crisis management, company culture, and how to keep employees happy, purpose-driven, and loyal.\xa0 \xa0

\n


If you liked this episode, check out these other Redefiner episodes:
\xb7\xa0\xa0Trust Your Gut: AXA\u2019s Thomas Buberl Talks Transformation and Reinvention
\xb7\xa0\xa0How to Lead Like a Legend with Samuel Tsien
\xb7\xa0\xa0Confessions of a Serial Entrepreneur with Mario Schlosser\xa0

BIO: Kevin A. Lobo, Chair and CEO, Stryker
Kevin A. Lobo has been CEO of Stryker since October 1, 2012, and also assumed the role of Chair of the Board on July 22, 2014. He joined Stryker in 2011 and had previously been Group President of Orthopaedics. Mr. Lobo serves on the board of directors for Parker Hannifin Corporation (NYSE:PH), the Advanced Medical Technology Association (AdvaMed) and the U.S.-India Business Council. He is also a member of the Business Roundtable and Business Council.

\n

Mr. Lobo has a broad business career across multiple industries. After holding finance positions with KPMG, Unilever and Kraft Canada, he spent eight years with Rhone-Poulenc, including roles based in Europe as Corporate Controller of a chemical spin-out and General Manager of Specialty Phosphates EMEA. He then spent eight years at Johnson & Johnson, including President of Ethicon Endo Surgery.